Feedback / Questions
MT-303 - CREATE Medicines
https://www.prnewswire.com/news-releases/create-medicines-doses-first-patient-in-frontline-hcc-trial-evaluating-mt-303-an-in-vivo-car-therapy-in-combination-with-standard-of-care-immunotherapy-302636561.html
Dec 9, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next